At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADPT Adaptive Biotechnologies Corp
Not Yet Opened 07-23 16:00:00 EDT
22.31
+0.36
+1.64%
盘后22.19
-0.12-0.54%
19:34 EDT
High22.91Low21.95Vol2.76M
Open21.95D1 Closing21.95Amplitude4.37%
Mkt Cap3.56BTradable Cap2.81BTotal Shares159.76M
T/O61.53MT/O Rate2.19%Tradable Shares126.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Adaptive Biotechnologies Corp Q2 revenue is expected to increase by 33.37%, and institutional views are predominantly bullish
Earnings Agent  ·  07-23 00:55
Earning Preview: Adaptive Biotechnologies Corp Q2 revenue is expected to increase by 33.37%, and institutional views are predominantly bullish
Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million
Reuters  ·  07:35
Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million
Is Adaptive Biotechnologies (ADPT) Fully Valued As Its Zacks Upgrade Lifts Earnings Hopes?
Simply Wall St.  ·  07-23 03:34
Is Adaptive Biotechnologies (ADPT) Fully Valued As Its Zacks Upgrade Lifts Earnings Hopes?
Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 5,000 Shares for $115,000
Reuters  ·  07-21
Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 5,000 Shares for $115,000
Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 105,762 Common Shares Worth $2.39 Million
Reuters  ·  07-18
Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 105,762 Common Shares Worth $2.39 Million
Adaptive Biotechnologies (ADPT) Stock Looks Reasonable On Cash Flow Yet Rich On Sales
Simply Wall St.  ·  07-11
Adaptive Biotechnologies (ADPT) Stock Looks Reasonable On Cash Flow Yet Rich On Sales
Adaptive Biotechnologies is Maintained at Equal-weight by Morgan Stanley
Dow Jones  ·  07-10
Adaptive Biotechnologies is Maintained at Equal-weight by Morgan Stanley
Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley
TIPRANKS  ·  07-09
Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley
U.S. Research Roundup-applied Materials, CME Group, NASDAQ
Reuters  ·  07-09
U.S. Research Roundup-applied Materials, CME Group, NASDAQ
Adaptive Biotech CSO Harlan S. Robins Disposes of USD 8.49 Million in Common Shares
Reuters  ·  07-08
Adaptive Biotech CSO Harlan S. Robins Disposes of USD 8.49 Million in Common Shares
Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?
Simply Wall St.  ·  07-07
Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?
Adaptive Biotechnologies CCO Susan Bobulsky Sells 487 Shares Worth $10,714
Reuters  ·  07-07
Adaptive Biotechnologies CCO Susan Bobulsky Sells 487 Shares Worth $10,714
Adaptive Biotechnologies Chief Commercial Officer Imm Med Sharon Benzeno Sells 165,802 Shares for $3.73 Million
Reuters  ·  07-01
Adaptive Biotechnologies Chief Commercial Officer Imm Med Sharon Benzeno Sells 165,802 Shares for $3.73 Million
Adaptive Biotechnologies Director Michelle Renee Griffin Disposes of 52,084 Common Shares Worth $1,051,855.12
Reuters  ·  06-30
Adaptive Biotechnologies Director Michelle Renee Griffin Disposes of 52,084 Common Shares Worth $1,051,855.12
Adaptive Biotechnologies (ADPT) Plans A Business Split, Is The Valuation Already Full?
Simply Wall St.  ·  06-29
Adaptive Biotechnologies (ADPT) Plans A Business Split, Is The Valuation Already Full?
Adaptive Biotechnologies is Maintained at Buy by Guggenheim
Dow Jones  ·  06-29
Adaptive Biotechnologies is Maintained at Buy by Guggenheim
Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim
TIPRANKS  ·  06-29
Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim
Adaptive Biotechnologies Issues $345 Million Convertible Notes
MT Newswires Live  ·  06-23
Adaptive Biotechnologies Issues $345 Million Convertible Notes
Adaptive Biotechnologies Corp - Issues $345 Mln in 0% Convertible Senior Notes Due 2031 - SEC Filing
THOMSON REUTERS  ·  06-23
Adaptive Biotechnologies Corp - Issues $345 Mln in 0% Convertible Senior Notes Due 2031 - SEC Filing
Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031
Reuters  ·  06-23
Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031

Introduction

Company Name.
Adaptive Biotechnologies Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Issue price:
--